65,437 trials
Leiomyoma · Uterine Hemorrhage
Primary: Percentage of Participants With Absence of Bleeding During the Last 35 Consecutive Days on Treatment — 1.8; 47.2; 58.3 percentage of participants
Pregnancy · Obstetric Labor · Parturition
Primary: Number of Participants With Primary Composite Outcome — 52; 40 Participants — p=0.20
Type 2 Diabetes Mellitus
Primary: Percent Change From Baseline in Mixed-meal Test (MMT) Glucose Area Under the Concentration-time Curve From Time 0 to 4 Hours to the End of Treatment (EOT) (Cohort 4)…
Adherence
Primary: Nightly Adherence — 4.83; 5.82; 4.82; 4.60 hours
Mucositis · Oral Complications · Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Primary: Groningen Radiotherapy-Induced Xerostomia (GRIX) Sticky Saliva Total Score Area Under the Curve (AUC) — 40.9; 27.2 score on a scale — p=0.1232
Healthy
Primary: Pharmacokinetics (PK) : Maximum Concentration (Cmax) of Dabigatran — 128; 148; 138 nanogram per milliliter (ng/mL)
Cancer
Primary: Occurrence of Dose-limiting Toxicities and Adverse Events — 0; 0; 0; 0 number of occurances
Severe Sepsis
Primary: Percentage of Incidence Rates of Serious Adverse Events (SAEs), Adverse Events (AEs), Immune-mediated AEs, AEs Leading to Discontinuation, and Deaths — 6.7; 43.8; 93.3…
Biliary Stricture
Primary: Count of Participants With Stent Patency at 90 Days — 22 Participants
Uveitis
Primary: Number of Participants With Adverse Events — 398; 101 participants
Depression · Anxious Depression · Major Depressive Disorder
Primary: Change in Hamilton Depression Rating Scale (HDRS) From Baseline/Minute 0 to 4 Hours Post-infusion. — -9.625 score on a scale — p=<0.01
Arthritis, Rheumatoid
Primary: Percentage of Participants Who Achieved Disease Activity Score for 28 Different Joints With C-reactive Protein Value (DAS28{CRP}) Remission (DAS28 <2.6) at Week 24 — 3…
Non-alcoholic Fatty Liver Disease
Primary: Percent Change From Baseline in Whole Liver Fat at Week 6 — -7.97; 2.84; -25.43 Percent Change — p=0.1654
Avian Influenza
Primary: Primary Immunogenicity Endpoint: Geometric Mean Titer (GMT) at Day 43 by Lot — 16.1; 17.0; 17.0; 128.6 geometric mean titer
Fat Disorder
Primary: Change in Fat Thickness at Final Follow-up Compared to Baseline — -1.76 millimeters